Kryształy C bezwodnego aripiprazolu i sposób ich wytwarzania oraz zawierające je kompozycja farmaceutyczna i farmaceutyczny stały preparat doustny

A pharmaceutical solid oral aripiprazole preparation is provided which has a) at least one dissolution rate measured after storage in the open at 25°C/60% RH for six months selected from the group consisting of 70 % or more at pH 4.5 after 60 minutes, and 55 % or more at pH 5.0 after 60 minutes; or...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	YAMADA SHOHEI, TAKAHASHI MASANORI, TOMINAGA MICHIAKI, AOKI SATOSHI, FUJIMOTO KIYOSHI, SHINHAMA KOICHI, NISHIOKA YOSHIHIRO, NAKAGAWA TOMONORI, KAWASAKI JUNICHI, TOMIKAWA KENJI, ISHIGAMI MAKOTO, ABE KAORU, TANIGUCHI YOUICHI, KOBAYASHI NORIYUKI, YABUUCHI TSUYOSHI, BANDO TAKUJI, UTSUMI NAOTO, OI YOSHIHIRO, FUJIMURA TSUTOMU
Format:	Patent
Sprache:	pol
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PERFORMING OPERATIONS PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SEPARATION SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TRANSPORTING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A pharmaceutical solid oral aripiprazole preparation is provided which has a) at least one dissolution rate measured after storage in the open at 25°C/60% RH for six months selected from the group consisting of 70 % or more at pH 4.5 after 60 minutes, and 55 % or more at pH 5.0 after 60 minutes; or b) at least one dissolution rate measured after storage in the open at 40°C/75% RH for 1 week selected from the group consisting of 70 % or more at pH 4.5 after 60 minutes, and 55 % or more at pH 5.0 after 60 minutes.